Principal Financial Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-10,213
Closed -$181K 2374
2018
Q3
$181K Sell
10,213
-131
-1% -$2.25K ﹤0.01% 2184
2018
Q2
$143K Buy
+10,344
New +$123K ﹤0.01% 2196
2015
Q2
Sell
-10,600
Closed -$67K 2243
2015
Q1
$67K Sell
10,600
-121
-1% -$698 ﹤0.01% 2128
2014
Q4
$67K Buy
10,721
+293
+3% +$1.79K ﹤0.01% 2141
2014
Q3
$63K Hold
10,428
﹤0.01% 2173
2014
Q2
$69K Buy
10,428
+1,962
+23% +$22.1K ﹤0.01% 2221
2014
Q1
$202K Sell
8,466
-6,629
-44% -$96.1K ﹤0.01% 2132
2013
Q4
$161K Hold
15,095
﹤0.01% 2200
2013
Q3
$201K Sell
15,095
-989
-6% -$15.6K ﹤0.01% 2120
2013
Q2
$211K Buy
+16,084
New +$217K ﹤0.01% 2065

Other funds holding ECYT

Principal Financial Group's ECYT Position: Q4 2018 in Review

Principal Financial Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 10,213 shares — an estimated $181K sold.

Principal Financial Group first reported a position in ECYT in Q2 2013 and held it in 10 quarters. The position peaked at $211K in Q2 2013. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Principal Financial Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Principal Financial Group sold 10,213 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $181K.
  • Principal Financial Group first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
  • Principal Financial Group's Endocyte, Inc. Common Stock position peaked at $211K in Q2 2013.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Principal Financial Group's 13F filing for Q4 2018, filed 14 Feb 2019.